Capricor Therapeutics Inc
CAPR
NASDAQ
Biotechnology
$6.65
USD
+2.44 (+57.96%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $252.50M
Volume 65.7M
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-114.59M
TTM
-108.1%
YoY
Operating Cash Flow
$-92.63M
TTM
-105.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | -100.0% | -100.0% | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.1 | 5.7 | 5.9 | 6.0 | 9.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 25.0 | 27.7 | 26.3 | 29.2 | 36.8 |
Operating Income | -25.0 | -27.7 | -26.3 | -29.2 | -36.8 |
EBITDA | -24.6 | -27.2 | -25.8 | -28.7 | -36.2 |
Other Income / Expense | -0.1 | 0.0 | -0.0 | 0.0 | -0.1 |
Total Other Income / Expense | 0.6 | 1.8 | 1.7 | -1.0 | 2.8 |
Income Before Income Taxes | -24.4 | -25.9 | -24.6 | -30.2 | -33.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -24.4 | -25.9 | -24.6 | -30.2 | -33.9 |
Consolidated Net Income / Loss | -24.4 | -25.9 | -24.6 | -30.2 | -33.9 |
Net Income Attributable to Common Shareholders | -24.4 | -25.9 | -24.6 | -30.2 | -33.9 |
Basic EPS | -$0.53 | -$0.57 | -$0.54 | -$0.62 | -$0.59 |
Diluted EPS | -$0.53 | -$0.57 | -$0.54 | -$0.62 | -$0.59 |
Basic Shares Outstanding | 45.6M | 45.7M | 45.7M | 48.9M | 57.4M |
Diluted Shares Outstanding | 45.6M | 45.7M | 45.7M | 48.9M | 57.4M |